• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
CU6 4.73% $5.09

CLARITY PHARMACEUTICALS LTD - Corporate Spotlight

Clarity Pharmaceuticals Ltd is an Australia-based clinical-stage radiopharmaceutical... Clarity Pharmaceuticals Ltd is an Australia-based clinical-stage radiopharmaceutical company. The Company is focused on developing theranostic (therapy and imaging) products, based on its platform SAR Technology. It is progressing seven clinical trials with its three key products, SARTATE, SAR-bisPSMA, and SAR-Bombesin. SARTATE is developed for diagnosing, staging, and treating cancers that express somatostatin receptor 2 (SSTR2), including neuroblastoma and neuroendocrine tumors (NETs). SAR-bisPSMA is developed for diagnosing, staging, and treating cancers that express Prostate Specific Membrane Antigen (PSMA). SAR-Bombesin is developed for identifying and selecting patients for subsequent treatment of cancers that express a specific receptor called the gastrin releasing peptide receptor (GRPr), including breast cancer and prostate cancer. It has a diverse range of products in clinical trials, which address both large indications as well as rare and orphan indications of cancer.More

No Corporate Spotlight currently available.

(20min delay)
Last
$5.09
Change
0.230(4.73%)
Mkt cap ! $1.586B
Open High Low Value Volume
$4.95 $5.11 $4.87 $4.562M 911.6K

Buyers (Bids)

No. Vol. Price($)
2 4449 $5.07
 

Sellers (Offers)

Price($) Vol. No.
$5.09 567 1
View Market Depth
Last trade - 16.10pm 26/06/2024 (20 minute delay) ?
Last
$5.09
  Change
0.230 ( 4.51 %)
Open High Low Volume
$4.88 $5.11 $4.88 374157
Last updated 15.59pm 26/06/2024 ?
CU6 (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.